Picture of Hyundai Pharmaceutical Co logo

004310 Hyundai Pharmaceutical Co Cashflow Statement

0.000.00%
kr flag iconLast trade - 00:00
HealthcareAdventurousMicro CapSucker Stock

Annual cashflow statement for Hyundai Pharmaceutical Co, fiscal year end - November 30th, KRW millions except per share, conversion factor applied.

2020
November 30th
2021
November 30th
2022
November 30th
2023
November 30th
2024
November 30th
Period Length:12 M12 M12 M12 M12 M
Source:Annual Audited AccountsAnnual Audited AccountsAnnual Audited AccountsAnnual Audited AccountsARS
Standards:
IFRS
IFRS
IFRS
IFRS
IFRS
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line2,187-3,173-1656,122-575
Depreciation
Amortisation
Non-Cash Items2,9435,3649,50717,5753,040
Unusual Items
Purchased R&D
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital1,562-1,037-1,016-31,542-8,526
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Other Assets
Change in Accounts Payable
Change in Accrued Expenses
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities10,8045,13211,624-4,545-2,373
Capital Expenditures-6,401-6,809-6,584-6,104-11,184
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items-5,9876,781-3,4073,0161,527
Sale of Fixed Assets
Sale/Maturity of Investment
Change in Net Investments
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities-12,388-27.7-9,991-3,088-9,657
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities7,4523,2517,005-6,4296,103
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash5,8688,3568,638-14,063-5,927